Rodman & Renshaw analyst Michael King Jr. initiates coverage on vTv Therapeutics (NASDAQ: VTVT) with a Buy rating and a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage